Gerke T, et al. - Researchers determined biological and prognostic role of tristetraprolin (a key node of NF-κB activation) in lethal prostate cancer, using in vitro assays and independent prostatectomy cohorts: nested case-control studies from Health Professionals Follow-up Study and Physicians’ Health Study, and prostatectomy samples from Cleveland Clinic, Mayo Clinic, Johns Hopkins and Memorial Sloan Kettering Cancer Center. They also used a Cornell University cohort to assess biopsies of metastatic castration–resistant prostate cancer (mCRPC) as well as prostatectomy samples from patients with localized disease. Findings revealed an inverse association between in vitro tristetraprolin expression and NF-κB–controlled genes, proliferation, and enzalutamide sensitivity. They found that lower levels of tristetraprolin in human prostate cancer prostatectomy tissue were related to more aggressive prostate cancer as well as could be an actionable prognostic and predictive biomarker.